Journal
BIOSCIENCE REPORTS
Volume 39, Issue -, Pages -Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BSR20193220
Keywords
-
Categories
Funding
- Department of Science and Technology-Science and Engineering Research Board (DST-SERB), Government of India under ECRA scheme [ECR/2016/001187]
- Department of Biotechnology (DBT), Science and Engineering Research Board-Department of Science and Technology, Government of India [BT/RLF/Re-entry/24/2014]
- ECRA scheme (SERB) [ECR/2016/001519]
- Dr. D.Y. Patil Vidyapeeth (Deemed to be University) [DPU/106/18/2015, DPU/17/2016]
Ask authors/readers for more resources
Dendritic cells (DCs) present exogenous antigens on major histocompatibility complex (MHC) class I molecules, thereby activating CD8(+) T cells, contributing to tumor elimination through a mechanism known as antigen cross-presentation. A variety of factors such as maturation state of DCs, co-stimulatory signals, T-cell microenvironment, antigen internalization routes and adjuvants regulate the process of DC-mediated antigen cross-presentation. Recently, the development of successful cancer immunotherapies may be attributed to the ability of DCs to cross-present tumor antigens. In this review article, we focus on the underlying mechanism of antigen cross-presentation and ways to improve antigen cross-presentation in different DC subsets. We have critically summarized the recent developments in the generation of novel nanovaccines for robust CD8(+) T-cell response in cancer. In this context, we have reviewed nanocarriers that have been used for cancer immunotherapeutics based on antigen cross-presentation mechanism. Additionally, we have also expressed our views on the future applications of this mechanism in curing cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available